Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-27 · 1381 Präparate · 72104 Quellenpassagen · 204 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Diacomit
Diacomit 250 mg powder for oral suspension in sachet · Abschnitt 4.5 · PDF-Seite 28
HOS-115424 · Präparat HOS-094267
- Statins (atorvastatin, simvastatin, etc.)
Increased risk of dose-dependent adverse reactions such as rhabdomyolysis (decreased hepatic
metabolism of cholesterol-lowering medicinal product).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage cd137e59946f600dbf043c8c1c3b73dbab9708939fe7b5eec2cc6278d615dad2 · Zeichen 4170–4361 im Abschnitt
Wechselwirkungen · Diacomit
Diacomit 500 mg powder for oral suspension in sachet · Abschnitt 4.5 · PDF-Seite 39
HOS-115459 · Präparat HOS-094267
- Statins (atorvastatin, simvastatin, etc.)
Increased risk of dose-dependent adverse reactions such as rhabdomyolysis (decreased hepatic
metabolism of cholesterol-lowering medicinal product).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T15:31:00Z · SHA-256 b075bfe26e1e2e48d4d17e44e4cfe0a1e4c38681d9170c43ecb8af51f184b9ab · Passage cd137e59946f600dbf043c8c1c3b73dbab9708939fe7b5eec2cc6278d615dad2 · Zeichen 4170–4361 im Abschnitt
Wechselwirkungen · Exjade
EXJADE 90 mg film-coated tablets EXJADE 180 mg film-coated tablets EXJADE 360 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-115539 · Präparat HOS-094307
Interaction with midazolam and other agents metabolised by CYP3A4
In a healthy volunteer study, the concomitant administration of deferasirox dispersible tablets and
midazolam (a CYP3A4 probe substrate) resulted in a decrease of midazolam exposure by 17% (90%
CI: 8% - 26%). In the clinical setting, this effect may be more pronounced. Therefore, due to a
possible decrease in efficacy, caution should be exercised when deferasirox is combined with
substances metabolised through CYP3A4 (e.g. ciclosporin, simvastatin, hormonal contraceptive
agents, bepridil, ergotamine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bepridil (HOS-085612) simvastatin (HOS-086158) ergotamine (HOS-086154) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage f562040d78fbc96dc181c53f9b11f16693eafd9872950d615981f15ee56e9636 · Zeichen 1120–1692 im Abschnitt
Wechselwirkungen · Exjade
EXJADE 90 mg granules in sachet EXJADE 180 mg granules in sachet EXJADE 360 mg granules in sachet · Abschnitt 4.5 · PDF-Seite 31
HOS-115573 · Präparat HOS-094307
Interaction with midazolam and other agents metabolised by CYP3A4
In a healthy volunteer study, the concomitant administration of deferasirox dispersible tablets and
midazolam (a CYP3A4 probe substrate) resulted in a decrease of midazolam exposure by 17% (90%
CI: 8% - 26%). In the clinical setting, this effect may be more pronounced. Therefore, due to a
possible decrease in efficacy, caution should be exercised when deferasirox is combined with
substances metabolised through CYP3A4 (e.g. ciclosporin, simvastatin, hormonal contraceptive
agents, bepridil, ergotamine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bepridil (HOS-085612) simvastatin (HOS-086158) ergotamine (HOS-086154) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T15:00:00Z · SHA-256 222a01b9b6233f96f99f56a88eeabc2cd5b2faff9038f592b1cc77a87d26915c · Passage f562040d78fbc96dc181c53f9b11f16693eafd9872950d615981f15ee56e9636 · Zeichen 1263–1835 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.3 · PDF-Seite 6
HOS-116288 · Präparat HOS-094447
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that
are highly dependent on CYP3A for clearance, which results in increased exposure to the
co-administered medicinal product. Therefore, concomitant treatment with such medicinal products
for which elevated plasma concentrations are associated with serious and/or life-threatening events is
contraindicated (applies to darunavir boosted with either ritonavir or cobicistat). These active
substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin, lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) cobicistat (HOS-088111) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage e2536d703754b5f39bebb9603c70a8d8759f7198e0666cec1af181c80f42d82c · Zeichen 1442–2753 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 49
HOS-116497 · Präparat HOS-094447
Co-administration of PREZISTA with low dose ritonavir, with active substances that are highly
dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with
serious and/or life-threatening events. These active substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 6a604bfa742092630f592a37246ad3ddd261ae7ceba904108fadd195ca4e43c8 · Zeichen 481–1534 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 87–88
HOS-116581 · Präparat HOS-094447
87
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) pimozide (HOS-085600) sildenafil (HOS-086162) lurasidone (HOS-086148) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 27a092d7005e5ab0411f0babdff280e728008e3766038685e07864d1fc35a1d1 · Zeichen 2308–2745 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.5 · PDF-Seite 20–21
HOS-116410 · Präparat HOS-094447
20
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Not studied. Concomitant use of bosentan When administered concomitantly
and boosted PREZISTA may increase with PREZISTA and low dose
plasma concentrations of bosentan. ritonavir, the patient’s tolerability
of bosentan should be monitored.
Bosentan is expected to decrease plasma
concentrations of darunavir and/or its Co-administration of PREZISTA
pharmacoenhancer. co-administered with cobicistat
(CYP3A induction) and bosentan is not recommended.
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A protease inhibitors
Elbasvir/grazoprevir Boosted PREZISTA may increase the Concomitant use of boosted
exposure to grazoprevir. PREZISTA and
(CYP3A and OATP1B inhibition) elbasvir/grazoprevir is
contraindicated (see section 4.3).
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to
boosted PREZISTA may increase the co-administer boosted PREZISTA
exposure to glecaprevir and pibrentasvir. with glecaprevir/pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
HERBAL PRODUCTS
St John's Wort Not studied. St John’s Wort is expected Boosted PREZISTA must not be
(Hypericum perforatum) to decrease the plasma concentrations of used concomitantly with products
darunavir or its pharmacoenhancers. containing St John’s Wort
(CYP450 induction) (Hypericum perforatum) (see
section 4.3). If a patient is already
taking St John’s Wort, stop
St John’s Wort and if possible
check viral levels. Darunavir
exposure (and also ritonavir
exposure) may increase on
stopping St John’s Wort. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John’s Wort.
HMG CO-A REDUCTASE INHIBITORS
Lovastatin Not studied. Lovastatin and simvastatin Increased plasma concentrations of
Simvastatin are expected to have markedly increased lovastatin or simvastatin may
plasma concentrations when cause myopathy, including
co-administered with boosted rhabdomyolysis. Concomitant use
PREZISTA. of boosted PREZISTA with
(CYP3A inhibition) lovastatin and simvastatin is
therefore contraindicated (see
section 4.3).
Atorvastatin atorvastatin AUC ↑ 3-4 fold When administration of
10 mg once daily atorvastatin Cmin ↑ ≈5.5-10 fold atorvastatin and boosted
atorvastatin Cmax ↑ ≈2 fold PREZISTA is desired, it is
#
darunavir/ritonavir recommended to start with an
atorvastatin dose of 10 mg once
atorvastatin AUC ↑ 290% Ω daily. A gradual dose increase of
atorvastatin may be tailored to the
atorvastatin Cmax ↑ 319% Ω
clinical response.
atorvastatin Cmin ND Ω
Ω
with darunavir/cobicistat 800/150 mg
Pravastatin pravastatin AUC ↑ 81%¶ When administration of pravastatin
40 mg single dose pravastatin Cmin ND and boosted PREZISTA is
pravastatin Cmax ↑ 63% required, it is recommended to
¶
an up to five-fold increase was seen in a start with the lowest possible dose
limited subset of subjects of pravastatin and titrate up to the
desired clinical effect while
monitoring for safety.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) cobicistat (HOS-088111) simvastatin (HOS-086158) glecaprevir (HOS-086297) hepatitis C virus (HOS-108813) grazoprevir (HOS-108815) ritonavir (HOS-084521) bosentan (HOS-086291) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 6c740a1d89386aee87cf1f30365ea4ce6beb0a0dc719c309b037ce4e6094f9e7 · Zeichen 57628–63489 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 62–63
HOS-116528 · Präparat HOS-094447
62
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Not studied. Concomitant use of bosentan When administered concomitantly
and PREZISTA co-administered with with PREZISTA and low dose
low dose ritonavir may increase plasma ritonavir, the patient’s tolerability
concentrations of bosentan. of bosentan should be monitored.
Bosentan is expected to decrease plasma
concentrations of darunavir and/or its
pharmacoenhancer.
(CYP3A induction)
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A protease inhibitors
Elbasvir/grazoprevir PREZISTA with low dose ritonavir may Concomitant use of PREZISTA
increase the exposure to grazoprevir. with low dose ritonavir and
(CYP3A and OATP1B inhibition) elbasvir/grazoprevir is
contraindicated (see section 4.3).
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to
boosted PREZISTA may increase the co-administer boosted PREZISTA
exposure to glecaprevir and pibrentasvir. with glecaprevir/pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
HERBAL PRODUCTS
St John's Wort Not studied. St John’s Wort is expected PREZISTA co-administered with
(Hypericum perforatum) to decrease the plasma concentrations of low dose ritonavir must not be
darunavir and ritonavir. used concomitantly with products
(CYP450 induction) containing St John’s Wort
(Hypericum perforatum) (see
section 4.3). If a patient is already
taking St John’s Wort, stop
St John’s Wort and if possible
check viral levels. Darunavir
exposure (and also ritonavir
exposure) may increase on
stopping St John’s Wort. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John’s Wort.
HMG CO-A REDUCTASE INHIBITORS
Lovastatin Not studied. Lovastatin and simvastatin Increased plasma concentrations of
Simvastatin are expected to have markedly increased lovastatin or simvastatin may
plasma concentrations when cause myopathy, including
co-administered with rhabdomyolysis. Concomitant use
PREZISTAco-administered with low of PREZISTA co-administered
dose ritonavir. with low dose ritonavir with
(CYP3A inhibition) lovastatin and simvastatin is
therefore contraindicated (see
section 4.3).
Atorvastatin atorvastatin AUC ↑ 3-4 fold When administration of
10 mg once daily atorvastatin Cmin ↑ ≈5.5-10 fold atorvastatin and PREZISTA
atorvastatin Cmax ↑ ≈2 fold co-administered with low dose
#
darunavir/ritonavir ritonavir is desired, it is
recommended to start with an
atorvastatin dose of 10 mg once
daily. A gradual dose increase of
atorvastatin may be tailored to the
clinical response.
Pravastatin pravastatin AUC ↑ 81%¶ When administration of pravastatin
40 mg single dose pravastatin Cmin ND and PREZISTA co-administered
pravastatin Cmax ↑ 63% with low dose ritonavir is required,
¶
an up to five-fold increase was seen in a it is recommended to start with the
limited subset of subjects lowest possible dose of pravastatin
and titrate up to the desired clinical
effect while monitoring for safety.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) simvastatin (HOS-086158) glecaprevir (HOS-086297) hepatitis C virus (HOS-108813) grazoprevir (HOS-108815) ritonavir (HOS-084521) bosentan (HOS-086291) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage f0e95b466409a0cf2f8a9197f2461639fabe461c2c18b467893f52ceb3fe5916 · Zeichen 48435–54296 im Abschnitt
Wechselwirkungen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 102–103
HOS-116618 · Präparat HOS-094447
102
ENDOTHELIN RECEPTOR ANTAGONISTS
Bosentan Not studied. Concomitant use of bosentan When administered concomitantly
and boosted PREZISTA may increase with PREZISTA and low dose
plasma concentrations of bosentan. ritonavir, the patient’s tolerability
Bosentan is expected to decrease plasma of bosentan should be monitored.
concentrations of darunavir and/or its
pharmacoenhancer. Co-administration of PREZISTA
(CYP3A induction) co-administered with cobicistat
and bosentan is not recommended.
HEPATITIS C VIRUS (HCV) DIRECT-ACTING ANTIVIRALS
NS3-4A protease inhibitors
Elbasvir/grazoprevir Boosted PREZISTA may increase the Concomitant use of boosted
exposure to grazoprevir. PREZISTA and
(CYP3A and OATP1B inhibition) elbasvir/grazoprevir is
contraindicated (see section 4.3).
Glecaprevir/pibrentasvir Based on theoretical considerations It is not recommended to
boosted PREZISTA may increase the co-administer boosted PREZISTA
exposure to glecaprevir and pibrentasvir. with glecaprevir/pibrentasvir.
(P-gp, BCRP and/or OATP1B1/3
inhibition)
HERBAL PRODUCTS
St John's Wort Not studied. St John’s Wort is expected Boosted PREZISTA must not be
(Hypericum perforatum) to decrease the plasma concentrations of used concomitantly with products
darunavir or its pharmacoenhancers. containing St John’s Wort
(CYP450 induction) (Hypericum perforatum) (see
section 4.3). If a patient is already
taking St John’s Wort, stop
St John’s Wort and if possible
check viral levels. Darunavir
exposure (and also ritonavir
exposure) may increase on
stopping St John’s Wort. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John’s Wort.
HMG CO-A REDUCTASE INHIBITORS
Lovastatin Not studied. Lovastatin and simvastatin Increased plasma concentrations of
Simvastatin are expected to have markedly increased lovastatin or simvastatin may
plasma concentrations when cause myopathy, including
co-administered with boosted rhabdomyolysis. Concomitant use
PREZISTA. of boosted PREZISTA with
(CYP3A inhibition) lovastatin and simvastatin is
therefore contraindicated (see
section 4.3).
Atorvastatin atorvastatin AUC ↑ 3-4 fold When administration of
10 mg once daily atorvastatin Cmin ↑ ≈5.5-10 fold atorvastatin and boosted
atorvastatin Cmax ↑ ≈2 fold PREZISTA is desired, it is
#
darunavir/ritonavir recommended to start with an
atorvastatin dose of 10 mg once
atorvastatin AUC ↑ 290% Ω daily. A gradual dose increase of
atorvastatin Cmax ↑ 319% Ω atorvastatin may be tailored to the
clinical response.
atorvastatin Cmin ND Ω
Ω
with darunavir/cobicistat 800/150 mg
Pravastatin pravastatin AUC ↑ 81%¶ When administration of pravastatin
40 mg single dose pravastatin Cmin ND and boosted PREZISTA is
pravastatin Cmax ↑ 63% required, it is recommended to
¶
an up to five-fold increase was seen in a start with the lowest possible dose
limited subset of subjects of pravastatin and titrate up to the
desired clinical effect while
monitoring for safety.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) protease (HOS-085623) lovastatin (HOS-086157) atorvastatin (HOS-086304) pibrentasvir (HOS-086298) cobicistat (HOS-088111) simvastatin (HOS-086158) glecaprevir (HOS-086297) hepatitis C virus (HOS-108813) grazoprevir (HOS-108815) ritonavir (HOS-084521) bosentan (HOS-086291) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage bf054a2c5f8c6d1a5be5b88714b31789a51a1dde2eabf2bbfe2ccb65fdbce96b · Zeichen 57100–62897 im Abschnitt
Wechselwirkungen · Sprycel
SPRYCEL 20 mg film-coated tablets SPRYCEL 50 mg film-coated tablets SPRYCEL 70 mg film-coated tablets SPRYCEL 80 mg film-coated tablets SPRYCEL 100 mg film-coated tablets SPRYCEL 140 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-116690 · Präparat HOS-094467
Active substances that may have their plasma concentrations altered by dasatinib
Concomitant use of dasatinib and a CYP3A4 substrate may increase exposure to the CYP3A4
substrate. In a study in healthy subjects, a single 100 mg dose of dasatinib increased AUC and Cmax
exposure to simvastatin, a known CYP3A4 substrate, by 20 and 37% respectively. It cannot be
excluded that the effect is larger after multiple doses of dasatinib. Therefore, CYP3A4 substrates
known to have a narrow therapeutic index (e.g. astemizole, terfenadine, cisapride, pimozide,
quinidine, bepridil or ergot alkaloids [ergotamine, dihydroergotamine]) should be administered with
caution in patients receiving dasatinib (see section 4.4).
In vitro data indicate a potential risk for interaction with CYP2C8 substrates, such as glitazones.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) ergot alkaloids (HOS-108807) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T12:05:00Z · SHA-256 c065657005bf3f51d58db1cb5b29a1453d36e1fc897c0adb5e47ed684f07722e · Passage 33c05cfcb37f1e735202cb4b1a867414e511fc2e264773d7381a4ba9bdd45322 · Zeichen 3141–3952 im Abschnitt
Wechselwirkungen · Sprycel
SPRYCEL 10 mg/mL powder for oral suspension · Abschnitt 4.5 · PDF-Seite 48
HOS-116741 · Präparat HOS-094467
Active substances that may have their plasma concentrations altered by dasatinib
Concomitant use of dasatinib and a CYP3A4 substrate may increase exposure to the CYP3A4
substrate. In a study in healthy subjects, a single 100 mg dose of dasatinib increased AUC and Cmax
exposure to simvastatin, a known CYP3A4 substrate, by 20 and 37% respectively. It cannot be
excluded that the effect is larger after multiple doses of dasatinib. Therefore, CYP3A4 substrates
known to have a narrow therapeutic index (e.g. astemizole, terfenadine, cisapride, pimozide,
quinidine, bepridil or ergot alkaloids [ergotamine, dihydroergotamine]) should be administered with
caution in patients receiving dasatinib (see section 4.4).
In vitro data indicate a potential risk for interaction with CYP2C8 substrates, such as glitazones.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cisapride (HOS-085610) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) ergot alkaloids (HOS-108807) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) dihydroergotamine (HOS-086152)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T12:05:00Z · SHA-256 c065657005bf3f51d58db1cb5b29a1453d36e1fc897c0adb5e47ed684f07722e · Passage 33c05cfcb37f1e735202cb4b1a867414e511fc2e264773d7381a4ba9bdd45322 · Zeichen 3142–3953 im Abschnitt
Wechselwirkungen · Exforge
Exforge 5 mg/80 mg film-coated tablets Exforge 5 mg/160 mg film-coated tablets Exforge 10 mg/160 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-117032 · Präparat HOS-094529
Simvastatin
Co-administration of multiple doses of 10 mg amlodipine with 80 mg simvastatin resulted in a 77%
increase in exposure to simvastatin compared to simvastatin alone. It is recommended to limit the dose
of simvastatin to 20 mg daily in patients on amlodipine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amlodipine (HOS-086287) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-19T14:05:00Z · SHA-256 c0f20d1cd1f31fe3cb10c75d388584e384179f190aefe9b5aa18ab44fe066abd · Passage 353b846284061ac7d64d1c6a469c577d4b443d33dcacb412c1659b7a7be66c23 · Zeichen 1728–1996 im Abschnitt
Wechselwirkungen · Januvia
Januvia 25 mg film-coated tablets Januvia 50 mg film-coated tablets Januvia 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-117231 · Präparat HOS-094553
In vitro data suggest that sitagliptin does not inhibit nor induce CYP450 isoenzymes. In clinical
studies, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide,
simvastatin, rosiglitazone, warfarin, or oral contraceptives, providing in vivo evidence of a low
propensity for causing interactions with substrates of CYP3A4, CYP2C8, CYP2C9, and organic
cationic transporter (OCT). Sitagliptin may be a mild inhibitor of p-glycoprotein in vivo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): simvastatin (HOS-086158) rosiglitazone (HOS-089664) glyburide (HOS-109273) warfarin (HOS-085950) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-31T16:35:00Z · SHA-256 684e79d7f33051f725c708828e69a058036bdb187bd94aedb78e22b6c6654103 · Passage 025a2a83a31c1f5a52afc014c96cac89b4b06a71dd290d0e3c786aeb772bd5ca · Zeichen 2638–3109 im Abschnitt
Wechselwirkungen · Xelevia
Xelevia 25 mg film-coated tablets Xelevia 50 mg film-coated tablets Xelevia 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-117554 · Präparat HOS-094641
In vitro data suggest that sitagliptin does not inhibit nor induce CYP450 isoenzymes. In clinical
studies, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide,
simvastatin, rosiglitazone, warfarin, or oral contraceptives, providing in vivo evidence of a low
propensity for causing interactions with substrates of CYP3A4, CYP2C8, CYP2C9, and organic
cationic transporter (OCT). Sitagliptin may be a mild inhibitor of p-glycoprotein in vivo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): simvastatin (HOS-086158) rosiglitazone (HOS-089664) glyburide (HOS-109273) warfarin (HOS-085950) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-01T17:33:00Z · SHA-256 f08aea892d6a7b9cf75b34f4b4074c9f6b71db0d601e841798224bb137a5083a · Passage 025a2a83a31c1f5a52afc014c96cac89b4b06a71dd290d0e3c786aeb772bd5ca · Zeichen 2638–3109 im Abschnitt
Wechselwirkungen · Galvus
Galvus 50 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-117605 · Präparat HOS-094657
Combination with amlodipine, ramipril, valsartan or simvastatin
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ramipril (HOS-089057) amlodipine (HOS-086287) simvastatin (HOS-086158) valsartan (HOS-088810)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-29T14:37:00Z · SHA-256 6d897e06d8818bc6a22f8fab8970bc5d1189a89a8f20d5e88a2537e7247206b7 · Passage a326943fea21fc46f2f2450fdbcf659e9b7fedcd1674b36e0836cc7f6e3f735c · Zeichen 737–800 im Abschnitt
Wechselwirkungen · Galvus
Galvus 50 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-117607 · Präparat HOS-094657
Drug-drug interaction studies in healthy subjects were conducted with amlodipine, ramipril, valsartan
and simvastatin. In these studies, no clinically relevant pharmacokinetic interactions were observed
after co-administration with vildagliptin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ramipril (HOS-089057) amlodipine (HOS-086287) simvastatin (HOS-086158) valsartan (HOS-088810)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-29T14:37:00Z · SHA-256 6d897e06d8818bc6a22f8fab8970bc5d1189a89a8f20d5e88a2537e7247206b7 · Passage e43db76b80e1b2737a56fa29338c5d7015f21608487bab66e4c0d5595eeca6f2 · Zeichen 802–1047 im Abschnitt
Wechselwirkungen · Copalia
Copalia 5 mg/80 mg film-coated tablets Copalia 5 mg/160 mg film-coated tablets Copalia 10 mg/160 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-117729 · Präparat HOS-094681
Simvastatin
Co-administration of multiple doses of 10 mg amlodipine with 80 mg simvastatin resulted in a 77%
increase in exposure to simvastatin compared to simvastatin alone. It is recommended to limit the dose
of simvastatin to 20 mg daily in patients on amlodipine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amlodipine (HOS-086287) simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-19T12:43:00Z · SHA-256 ff02e70e0f3fe7a3fb94d2963c4154f946936506ae5d98b0833bbd070c73ea06 · Passage 353b846284061ac7d64d1c6a469c577d4b443d33dcacb412c1659b7a7be66c23 · Zeichen 1728–1996 im Abschnitt
Wechselwirkungen · Dafiro
Dafiro 5 mg/80 mg film-coated tablets Dafiro 5 mg/160 mg film-coated tablets Dafiro 10 mg/160 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-117768 · Präparat HOS-094689
Simvastatin
Co-administration of multiple doses of 10 mg amlodipine with 80 mg simvastatin resulted in a 77%
increase in exposure to simvastatin compared to simvastatin alone. It is recommended to limit the dose
of simvastatin to 20 mg daily in patients on amlodipine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): simvastatin (HOS-086158)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-19T13:43:00Z · SHA-256 79620834a2f80d9411f50ae6b7ff4251fbeff4573f3af37e14d730cfb3d0f1a2 · Passage 353b846284061ac7d64d1c6a469c577d4b443d33dcacb412c1659b7a7be66c23 · Zeichen 1727–1995 im Abschnitt
Wechselwirkungen · Ranexa (previously Latixa)
Ranexa 375 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-118255 · Präparat HOS-094791
Dose adjustment of sensitive CYP3A4 substrates (e.g. simvastatin, lovastatin) and CYP3A4 substrates
with a narrow therapeutic range (e.g. ciclosporin, tacrolimus, sirolimus, everolimus) may be required
as RANEXA may increase plasma concentrations of these drugs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) simvastatin (HOS-086158) tacrolimus (HOS-085202) everolimus (HOS-086310) sirolimus (HOS-085172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage 42333281082168baf3e258a472cc235246a9d9fb4f172fbca1447d41e84cb85c · Zeichen 2630–2892 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.